CRISPR Therapeutics CRSP Total debt

Total debt at other companies

Intellia TherapeuticsNTLA

$73.41M-28.4%

Allogene TherapeuticsALLO

$81.05M-8.9%

Beam TherapeuticsBEAM

$250.82M+58.6%

Sana BiotechnologySANA

$75.33M-17.5%

Design Therapeutics, Inc.DSGN

$2.73M+27.7%

Prime MedicinePRME

$112.48M-6.1%

FAQ

What is CRISPR Therapeutics's total debt?

CRISPR Therapeutics (CRSP) reported total debt of $787.64M in Q1 2026.

How has CRISPR Therapeutics's total debt changed year-over-year?

CRISPR Therapeutics's total debt increased by 259.1% year-over-year, from $219.36M to $787.64M.

What is the long-term trend for CRISPR Therapeutics's total debt?

Over 5 years (2020 to 2025), CRISPR Therapeutics's total debt has grown at a 27.5% compound annual growth rate (CAGR), from $61.43M to $206.75M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.